The abstract is read at the publisher; the summary is JClub's.
In RAS/BRAF wild-type, left-sided metastatic colorectal cancer, m-FOLFOXIRI plus cetuximab improved median progression-free survival to 14.8 vs 11.9 months versus bevacizumab.
- Why it matters: Survival benefits beyond tumor shrinkage are uncertain for RAS/BRAF wild-type mCRC, especially by tumor sidedness and key clinical subgroups.
- What they did: The randomized phase II DEEPER trial (jRCTs061180022) compared m-FOLFOXIRI plus cetuximab versus bevacizumab, analyzing final OS and PFS in the per-protocol set with extended follow-up and subgroup analyses for liver-limited disease and sex.
- The result: Overall survival showed a 50.2 vs 40.2 month median advantage for cetuximab (HR 0.74; 95% CI, 0.53 to 1.05), with exploratory longer OS signals in males (HR 0.59; P = .016) and extrahepatic disease (HR 0.60; P = .014).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.